Compare MPLX LP (MPLX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Sanofi SA — how do they compare? MPLX LP trades at $56.22 (market cap $58.11B), while Sanofi SA trades at $40.15 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MPLX | SNY | |
|---|---|---|
Market Cap | $58.11B | $95.18B |
Volume | 687,483 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $60.51 | $52.34 |
52-Week Low | $47.80 | $39.51 |
Enterprise Value | $83.22B | $114.48B |
Dividend Yield | 7.51% | 6.01% |
Typical Hold Time | — | 94 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.86, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and dividend payments. Technical indicators show mixed signals with RSI neutral but ADX suggesting selling pressure.
MPLX offers value with a 12.33 P/E ratio and strong profitability metrics, but faces headwinds from recent earnings misses and energy market volatility. The stock presents income appeal with dividend coverage, though investors should monitor execution on future earnings and energy price sensitivity.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
